-
公开(公告)号：US07407973B2
公开(公告)日：2008-08-05
申请号：US10574631
申请日：2004-10-21
Applicant: Osman N. Ozes , Lawrence M. Blatt , Scott D. Seiwert
Inventor： Osman N. Ozes , Lawrence M. Blatt , Scott D. Seiwert
IPC: A61K31/445
CPC classification number: A61K31/47 , A61K31/4412 , A61K38/212 , A61K38/217 , A61K45/06 , G01N33/5091 , Y02A50/411 , A61K2300/00
Abstract: The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
Abstract translation: 本发明提供了治疗病症的方法以及在个体细胞中抑制应激活化蛋白激酶（SAPK）的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物 ; 将来自个体的生物样品中的后处理SAPK活性水平与预处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。 本发明提供了治疗病症的方法以及在个体细胞中抑制SAPK的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物; 将来自个体的生物样品中的第二后处理SAPK活性水平与第一后处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。
-
公开(公告)号：US08299021B2
公开(公告)日：2012-10-30
申请号：US13450885
申请日：2012-04-19
Applicant: Lawrence M Blatt , Scott D Seiwert , Steven W Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
Inventor： Lawrence M Blatt , Scott D Seiwert , Steven W Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC: A61K38/00
CPC classification number: C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Abstract translation: 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
23.发明申请公开(公告)号：US20120208995A1
公开(公告)日：2012-08-16
申请号：US13450885
申请日：2012-04-19
Applicant: Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
Inventor： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC: C07D498/18
CPC classification number: C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Abstract translation: 实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
24.发明申请公开(公告)号：US20120094897A1
公开(公告)日：2012-04-19
申请号：US13232815
申请日：2011-09-14
Applicant: Brad Buckman , John B. Nicholas , Vladimir Serebryany , Scott D. Seiwert
Inventor： Brad Buckman , John B. Nicholas , Vladimir Serebryany , Scott D. Seiwert
CPC classification number: C07D513/22 , A61K38/00 , C07K5/0808
Abstract: The embodiments provide compounds of the general Formulae I, and II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Abstract translation: 实施方案提供了通式I和II的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
25.发明申请METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS 审中-公开用P38抑制剂化合物治疗ATRIAL FIBRILLATION的方法公开(公告)号：US20120046321A1
公开(公告)日：2012-02-23
申请号：US13244707
申请日：2011-09-26
Applicant: Jeff Olgin , Susan Eisenberg , Lawrence M. Blatt , Scott D. Seiwert , Karl Kossen
Inventor： Jeff Olgin , Susan Eisenberg , Lawrence M. Blatt , Scott D. Seiwert , Karl Kossen
IPC: A61K31/4418 , A61P9/06 , A61P9/00
CPC classification number: A61K31/47
Abstract: The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).
Abstract translation: 本文公开的发明一般涉及可用于治疗或预防心房颤动（AF）的化合物和方法。
-
Patent Agency Ranking
公开(公告)号：US08119592B2
公开(公告)日：2012-02-21
申请号：US12089895
申请日：2006-10-10
Applicant: Leonid Beigelman , Scott D. Seiwert , Lawrence Blatt , Steven Andrews , Julia Haas
Inventor： Leonid Beigelman , Scott D. Seiwert , Lawrence Blatt , Steven Andrews , Julia Haas
IPC: A61K38/12
CPC classification number: C07D487/04 , C07D471/04
Abstract: Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV.
Abstract translation: 具有本文所述结构的大环化合物可用于抑制丙型肝炎病毒（HCV）的复制。 在优选的实施方案中，所述化合物对NS3蛋白酶和HCV的NS3解旋酶均有活性。
-
27.发明申请NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开HEPATITIS C病毒复制的新型MACROCYCLIC抑制剂公开(公告)号：US20110059047A1
公开(公告)日：2011-03-10
申请号：US12949700
申请日：2010-11-18
Applicant: Scott D. Seiwert , Leonid Beigelman , Brad Buckman , Antitsa Dimitrova Stoycheva , Steven B. Porter , Williamson Ziegler Bradford , Vladimir Serebryany
Inventor： Scott D. Seiwert , Leonid Beigelman , Brad Buckman , Antitsa Dimitrova Stoycheva , Steven B. Porter , Williamson Ziegler Bradford , Vladimir Serebryany
CPC classification number: C07D471/04 , A61K31/407 , A61K31/4709 , A61K31/4725 , A61K31/4738 , A61K31/517 , A61K31/7056 , A61K38/212 , A61K38/217 , A61K45/06 , C07D487/04 , C07K5/123 , A61K2300/00
Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Abstract translation: 实施方案提供了通式I，II，III，IV，V，VI，VII和X的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。
-
公开(公告)号：US07728013B2
公开(公告)日：2010-06-01
申请号：US11431132
申请日：2006-05-09
Applicant: Lawrence M. Blatt , Scott D. Seiwert , Leonid Beigelman , Ramachandran Radhakrishnan , Karl Kossen , Vladimir Serebryany
Inventor： Lawrence M. Blatt , Scott D. Seiwert , Leonid Beigelman , Ramachandran Radhakrishnan , Karl Kossen , Vladimir Serebryany
IPC: A61K31/44 , A01N43/40 , C07D213/62 , C07D213/44
CPC classification number: A61K31/4412 , A61K31/44 , A61K31/444 , A61K31/45 , A61K31/4704 , A61K31/7052 , A61K47/56 , A61K47/58 , C07D213/16 , C07D213/26 , C07D213/63 , C07D213/64 , C07D213/69 , C07D215/227 , C07H15/26 , C07K1/1077 , C08F289/00 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
Abstract translation: 公开了用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物表现出低的抑制至少一种p38MAPK的能力; 并且其中所述接触以对所述化合物抑制至少一种p38MAPK的低百分比抑制浓度的SAPK-调节浓度进行。 还公开了吡非尼酮的衍生物。 这些衍生物可以调节应激活化蛋白激酶（SAPK）系统。
-
29.发明申请公开(公告)号：US20100099851A1
公开(公告)日：2010-04-22
申请号：US12581723
申请日：2009-10-19
Applicant: Jin Hong , Scott D. Seiwert , Lawrence M. Blatt
Inventor： Jin Hong , Scott D. Seiwert , Lawrence M. Blatt
IPC: C07K14/555
CPC classification number: A61K38/212
Abstract: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.
-
30.发明申请公开(公告)号：US20100029578A1
公开(公告)日：2010-02-04
申请号：US12091161
申请日：2006-11-01
Applicant: Jeff Olgin , Susan Eisenberg , Lawrence M. Blatt , Scott D. Seiwert , Karl Kossen
Inventor： Jeff Olgin , Susan Eisenberg , Lawrence M. Blatt , Scott D. Seiwert , Karl Kossen
IPC: A61K31/7052 , C07D213/78 , C07D213/62 , C07H15/00 , A61K31/44 , A61K31/444 , A61P9/00
CPC classification number: A61K31/47
Abstract: The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).
Abstract translation: 本文公开的发明一般涉及可用于治疗或预防心房颤动（AF）的化合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.048 seconds)
